Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Debt / NOTE 0.625% 4/0
-
Number of holders
-
0
-
Total principal
-
0
-
Principal change
-
-393M
-
Total reported value, excl. options
-
$0
-
Value change
-
-$393M
-
Number of sells
-
-38
Significant Holders of SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 as of Q2 2023
0 filings reported holding 868459AD0 - SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 as of Q2 2023.
SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 has 0 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $0 of principal
.
Largest 10 bondholders include GRIMES & COMPANY, INC. ($0 of principal), Raymond James Financial Services Advisors, Inc. ($0 of principal), EXCALIBUR MANAGEMENT CORP ($0 of principal), CITIGROUP INC ($0 of principal), Russell Investments Group, Ltd. ($0 of principal), PIPER SANDLER & CO. ($0 of principal), JPMORGAN CHASE & CO ($0 of principal), SCHRODER INVESTMENT MANAGEMENT GROUP ($0 of principal), Penn Mutual Asset Management, LLC ($0 of principal), and OAKTREE CAPITAL MANAGEMENT LP ($0 of principal).
This table shows the top 0 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.